Trial · NCT03303235
Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections
NCT03303235, Early phase 1, Withdrawn, Johns Hopkins University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections. Trials, record NCT03303235. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03303235
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections
- NCT number
- NCT03303235
- Status
- Withdrawn
- Phases
- Early phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Uterine Atony, Uterine Tone Disorders, Postpartum Hemorrhage
- Interventions
- Methylergonovine
- First posted
- 2017-10-05
- Last updated
- 2020-08-03
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to achieve "adequate" uterine tone | 10 minutes | Our primary objective is to determine the time to achieve "adequate" uterine tone with either intramuscular (IM) dose versus intravenous (IV) dose methylergonovine, when oxytocin has failed to do so in cesarean sections. |
| Secondary | Dose that achieves "adequate" uterine tone | 3 minutes | Determining dose that achieves "adequate" uterine tone as defined by obstetricians on a qualitative numerical scale defined prior to the study (0 to 10 with 0 being inability of uterus to contract (i.e. uterine atony) to 10 being fully contracting uterus; "adequate" would be \>5 on the scale) |
| Secondary | Need for additional uterotonic agents | 3 minutes | Quantifying need for additional uterotonic agents as outlined by the postpartum hemorrhage guidelines set forth by ACOG |
| Secondary | Frequency of side effects of methylergonovine | 30 minutes | Determining frequency of side effects of methylergonovine, including blood pressure changes, especially if elevated \>20% preoperative level), headache, nausea, and vomiting |
| Secondary | Need for vasopressors | 3 minutes | To determine if the patient requires a vasopressor (including phenylephrine, ephedrine, epinephrine, norepinephrine or vasopressin)? |
| Secondary | Estimated blood loss | 2 hours | Utilizing estimated blood loss by suction canister + estimated weight of blood on surgical lap |
| Secondary | Computed blood loss | 2 hours | Calculating changes in hematocrit (Hct preop - Hct postop) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03303235
GET https://conductscience.org/api/trials/v1/NCT03303235/registered